DK2080012T3 - Fremgangsmåder til analyse af testforbindelser på forbundne receptorer. - Google Patents

Fremgangsmåder til analyse af testforbindelser på forbundne receptorer.

Info

Publication number
DK2080012T3
DK2080012T3 DK07815525.6T DK07815525T DK2080012T3 DK 2080012 T3 DK2080012 T3 DK 2080012T3 DK 07815525 T DK07815525 T DK 07815525T DK 2080012 T3 DK2080012 T3 DK 2080012T3
Authority
DK
Denmark
Prior art keywords
methods
test compounds
associated receptors
analyzing test
analyzing
Prior art date
Application number
DK07815525.6T
Other languages
English (en)
Inventor
Kevin Donald George Pfleger
Ruth Marie Seeber
Karin Ann Eidne
Heng Boon See
Original Assignee
Dimerix Bioscience Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006906292A external-priority patent/AU2006906292A0/en
Application filed by Dimerix Bioscience Pty Ltd filed Critical Dimerix Bioscience Pty Ltd
Application granted granted Critical
Publication of DK2080012T3 publication Critical patent/DK2080012T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07815525.6T 2006-11-10 2007-11-09 Fremgangsmåder til analyse af testforbindelser på forbundne receptorer. DK2080012T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006906292A AU2006906292A0 (en) 2006-11-10 Detection System and Uses Therefor
PCT/AU2007/001722 WO2008055313A1 (en) 2006-11-10 2007-11-09 Detection system and uses therefor

Publications (1)

Publication Number Publication Date
DK2080012T3 true DK2080012T3 (da) 2013-06-17

Family

ID=39364112

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07815525.6T DK2080012T3 (da) 2006-11-10 2007-11-09 Fremgangsmåder til analyse af testforbindelser på forbundne receptorer.

Country Status (11)

Country Link
US (3) US20100234417A1 (da)
EP (3) EP2080012B1 (da)
JP (2) JP5313149B2 (da)
KR (1) KR20090083925A (da)
CN (1) CN101657715B (da)
AU (2) AU2007317204A1 (da)
CA (2) CA2669088C (da)
DK (1) DK2080012T3 (da)
IL (1) IL198639A (da)
WO (2) WO2008055313A1 (da)
ZA (1) ZA200903529B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
BRPI0813583A2 (pt) * 2007-07-13 2014-12-30 Prometheus Lab Inc Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo
EP2210104A4 (en) * 2007-11-01 2011-02-23 Univ Arizona State CELL-FREE PROCEDURE FOR DETECTING PROTEIN-LIGAND INTERACTIONS
WO2009108637A1 (en) 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
JP2012521967A (ja) * 2009-03-27 2012-09-20 ディメリックス バイオサイエンス ピーティーワイ リミテッド 新規な受容体のヘテロ二量体／ヘテロオリゴマー
ES2627909T3 (es) 2009-07-15 2017-08-01 Diatech Holdings, Inc. Selección de fármacos para el tratamiento del cáncer gástrico usando matrices basadas en anticuercuerpos
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
CA2821985C (en) 2011-01-11 2019-07-09 Dimerix Bioscience Pty Ltd Combination therapy
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
IE20120542A1 (en) * 2012-12-19 2014-07-02 Provost Fellows Foundation Scholars And Other Members Of Board Of The College Of The Holy And Undivi Novel TRH binding site in human CNS
KR102192554B1 (ko) 2013-03-13 2020-12-18 에스케이바이오팜 주식회사 탈력발작의 치료
JP6863897B2 (ja) 2015-01-09 2021-04-21 アダルタ・リミテッド Ｃｘｃｒ４結合分子
KR102085554B1 (ko) * 2018-02-21 2020-03-06 영남대학교 산학협력단 사카로마이세스 세레비시애의 g-단백질 연결 수용체에 대한 알파 팩터의 친화도 측정방법
CN111089971B (zh) * 2019-12-11 2021-01-15 浙江大学 一种膜电位调控下的蛋白相互作用定量检测装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
EP1137940A4 (en) * 1998-10-23 2004-06-02 Glaxo Group Ltd METHOD FOR IDENTIFYING LIGANDS OF NUCLEAR RECEPTORS
DE60026603T2 (de) 1999-12-22 2007-03-01 PerkinElmer BioSignal Inc., Montréal Biolumineszenz-Resonanz-Energie-Transfer(BRET)-System mit großer spektraler Auflösung zwischen der Donator- und der Akzeptoremissionswellenlänge sowie dessen Verwendun
US6893827B1 (en) * 2000-02-07 2005-05-17 Applera Corporation Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
NZ554913A (en) * 2001-12-14 2009-01-31 Targacept Inc Methods and compositions for the treatment of central nervous system disorders
FR2836475B1 (fr) * 2002-02-26 2007-02-23 Aventis Pharma Sa Procede de detection de ligands du recepteur de la leptine
DE10218785A1 (de) 2002-04-26 2003-11-13 Infineon Technologies Ag Halbleiterspeichereinrichtung und Betriebsverfahren für eine Halbleiterspeichereinrichtung
DE10230141B4 (de) * 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
JP2004093527A (ja) 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
ATE500270T1 (de) * 2003-05-20 2011-03-15 Univ Glasgow Materialien und methoden die sich auf g-protein gekoppelte rezeptor oligomere beziehen
US7049076B2 (en) * 2003-07-09 2006-05-23 Sentigen Biosciences, Inc. Method for assaying protein—protein interaction
US7488583B2 (en) 2003-09-25 2009-02-10 Odyssey Thera, Inc. Fragment complementation assays for G-protein-coupled receptors and their signaling pathways
WO2005050182A1 (en) * 2003-11-19 2005-06-02 Dimerix Biosciences Pty Ltd Resonance energy transfer assay system for multi-component detection
CN1627072A (zh) * 2003-12-11 2005-06-15 中国人民解放军军事医学科学院卫生学环境医学研究所 一种蛋白质芯片，其制备方法及用途

Also Published As

Publication number Publication date
EP2080012A1 (en) 2009-07-22
US20100021457A1 (en) 2010-01-28
ZA200903529B (en) 2010-03-31
WO2008055314A1 (en) 2008-05-15
CN101657715A (zh) 2010-02-24
JP2010509572A (ja) 2010-03-25
AU2007317204A1 (en) 2008-05-15
EP2078037A4 (en) 2010-01-27
WO2008055313A1 (en) 2008-05-15
IL198639A (en) 2015-01-29
US20130065253A1 (en) 2013-03-14
CN101657715B (zh) 2012-07-25
EP2080012A4 (en) 2010-01-27
AU2007317203A1 (en) 2008-05-15
US8568997B2 (en) 2013-10-29
CA2669088A1 (en) 2008-05-15
JP2010510175A (ja) 2010-04-02
US8283127B2 (en) 2012-10-09
CA2669088C (en) 2016-04-05
EP2080012B1 (en) 2013-03-20
EP2078037A1 (en) 2009-07-15
CA2669185A1 (en) 2008-05-15
US20100234417A1 (en) 2010-09-16
IL198639A0 (en) 2010-02-17
KR20090083925A (ko) 2009-08-04
EP2605015A1 (en) 2013-06-19
JP5313149B2 (ja) 2013-10-09
AU2007317203B2 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
DK2080012T3 (da) Fremgangsmåder til analyse af testforbindelser på forbundne receptorer.
DK3494882T3 (da) Indretning til overvågning af analytter
DK1875401T3 (da) Indretning til kvantitativ analyse af en metabolitprofil
DK1946047T3 (da) Apparat til interferometrisk måling
DK2557180T3 (da) Fremgangsmåder til påvisning af autoimmune lidelser
DK2054711T3 (da) Fremgangsmåde til fremstilling af mikroarrays
DK2378980T3 (da) Anordning til udtagning af materialeprøver fra et dyr
DK3017769T3 (da) Nålstruktur til udførelse af nålbiopsier
DK2902690T3 (da) Anomalidetektor til rørledninger
DE602006007563D1 (de) Agonisten
FR2881809B1 (fr) Bloqueur de lacet rapide
SE0702055L (sv) Andedräktsanalysator
DK3404114T3 (da) Fremgangsmåde til detektering af AFLP-baseret polymorfisme med højt gennemløb
DK1976410T3 (da) Fremgangsmåde til analyse af hår
BRPI0813531A2 (pt) Método para estabelecimento de um enlace de sinal hrpd
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
NO20052144D0 (no) Anordning ved ringromspakning
DK1764589T3 (da) Fremgangsmåde til afprøvning af en Coriolis flowmåler
NO20050592A (no) Apparat for strømningsmåling
DK3106874T3 (da) Fremgangsmåde til detektering af cancer
DE602007013889D1 (de) Dimere verbindungen für einen fgf-rezeptor-agonisten
DE502007005744D1 (de) Schallgedämpftes, gasführendes Bauteil
DK2220488T3 (da) Fremgangsmåde til udførelse af en test til neutralisering af antistoffer
DK2094728T3 (da) Fremgangsmåder til anvendelse for human-adapterende monoklonale antistoffer
DK1931998T3 (da) Fremgangsmåde til kvantificering af allergener